A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

@article{Jakubowiak2012AP1,
  title={A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.},
  author={Andrzej Jakubowiak and Dominik Dytfeld and Kent A. Griffith and Daniel J Lebovic and David H Vesole and Sundar Jagannath and Ammar Al-Zoubi and Tara Anderson and Brian Nordgren and Kristen Detweiler-Short and K Stockerl-Goldstein and Asra Ahmed and Terri Jobkar and Diane E Durecki and Kathryn McDonnell and Melissa A Mietzel and Daniel Couriel and Mark Kaminski and Ravi Vij},
  journal={Blood},
  year={2012},
  volume={120 9},
  pages={1801-9}
}
This phase 1/2 study in patients with newly diagnosed multiple myeloma (N = 53) assessed CRd--carfilzomib (20, 27, or 36 mg/m2, days 1, 2, 8, 9, 15, 16 and 1, 2, 15, 16 after cycle 8), lenalidomide (25 mg/d, days 1-21), and weekly dexamethasone (40/20 mg cycles 1-4/5+)--in 28-day cycles. After cycle 4, transplantation-eligible candidates underwent stem cell collection (SCC) then continued CRd with the option of transplantation. The maximum planned dose level (carfilzomib 36 mg/m2) was expanded… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 13 times over the past 90 days. VIEW TWEETS
131 Citations
37 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 131 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 37 references

A summary of safety and efficacy data achieved with long - term carfilzomib ( CFZ ) treatment in patients with relapsed and / or refractory multiple myeloma ( R / R MM ) [ abstract ]

  • D Siegel, J Kaufman, M Wang
  • Haematologica
  • 2011

A summary of safety and efficacy data achieved with longterm carfilzomib (CFZ) treatment in patients with relapsed and/or refractory multiple myeloma

  • D Siegel, J Kaufman, M Wang, e. al
  • (R/R MM) [abstract]. Haematologica
  • 2011

Final results from the bortezomib-naive group of PX-171004, a phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory MM [abstract]. Blood

  • R Vij, JL Kaufman, AJ Jakubowiak
  • Abstract
  • 2011

Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis [abstract

  • S Singhal, DS Siegel, T Martin
  • Blood ( ASH Annual Meeting Abstracts )
  • 2011

Similar Papers

Loading similar papers…